Efficacy Results on Topical Psoriasis Cream expected to be completed in April
Here is why:
According to the study described in the Patent WO2016/103254 " Use of Cannabis to Treat Psoriasis" the duration of Efficacy Study is:
1)Screening phase up to 3 weeks;
2)Treatment phase 16 weeks;
3)Follow up phase 4 weeks;
Since it has been stated in last year press release that the Efficacy Test started in November and in the February 8k was clarified the excellent results at the Mid Point of the study, assuming a 16 weeks treatment phase study was at its half on 1st February, then I would count from 1st February another 8 weeks of treatment plus 4 weeks of Follow up.
Which means that the Study is to be completed this or next week
This is all confirmed in 27th February PR:
" OWCP today announced it has received Institutional Review Board (IRB) approval to conduct safety testing on its proprietary topical crème compound for the treatment of psoriasis and related skin conditions. The approval follows the Company's February 1, 2017 8K filing announcing an extension to the size and scope of its efficacy study on the same compound, which began in November 2106."
And again in March 21 PR:
"In October 2016, OWC announced that it was in the final phase of pre-clinical efficacy testing for its topical psoriasis cream and also announced a parallel test to assess the efficacy of the formulation in treating psoriasis in human skin tissue. "
Safety Study on Topical Psoriasis Cream
On the other hand before commercialization we still miss the last step which is the Safety Study following IRB Approval which is different from the efficacy study ongoing.
From 21st March PR:
"We are very pleased to say that OWC is expecting the topical cream product readiness during 2017 Q2 (then corrected to beginning of Q3) and, subject to positive completion of our safety IRB approved study and obtaining regulatory approvals from applicable jurisdictions, we should be able to offer our topical cream to those who suffer from psoriasis in the near term."
According to annual report this Safety Study is supposed to start in April and it will last 12-16 weeks, which means it is to be completed within July: this confirm OWCP plan to commercialize the Topical Cream this Summer 2017 in US MMJ States and Euroe (according to MMJ legislation) thanks to the agreemnt respectively with MEdMar and MichePro.
And no not forget that IRB Approval for the Cream is valid beyond the Psoriasis:
"OWC's scientific team to submit an operating plan within 60 to 90 days to conduct double-blind efficacy tests of our cannabinoid-based topical cream on other skin disorders and conditions."
therefore to be completed in Q2, we should also expect a PR describing a a new study for application of the cream for other diseases
In addtion OWCP Will most likely apply for an IRB approval for Multiple Myeloma in this Q2 quarter to have a clinical trial in Q3.
News 
Market Data 
Discover 
